Package leaflet warnings - Levitra/Vivanza (Vardenafil)

Do not take Levitra

* If you are allergic (hypersensitive) to vardenafil or any of the other ingredients of Levitra. See the ingredients in section 6. Signs of an allergic reaction include a rash, itching, swollen face or lips and shortness of breath.

* If you are taking medicines containing nitrates, such as glycerol trinitrate for angina, or nitric oxide donors, such as amyl nitrite. Taking these medicines with Levitra could seriously affect your blood pressure.

* If you are taking ritonavir or indinavir, medicines for HIV.

* If you are over 75 years of age and are taking ketoconazole or itraconazole, anti-fungal medicines

* If you have a severe heart or liver problem

* If you are having kidney dialysis

* If you have recently had a stroke or heart attack

* If you have or have had low blood pressure

* If your family has a history of degenerative eye diseases (such as retinitis pigmentosa)

* If you have ever had a condition involving loss of vision due to damage to the optic nerve from insufficient blood supply known as non-arteritic ischemic optic neuropathy (NAION)

Take special care with Levitra

* If you have heart trouble. It may be risky for you to have sex

* If you suffer from irregular heart beat (cardiac arrythmia) or inherited heart diseases affecting your electrocardiogram

* If you have a physical condition affecting the shape of the penis. This includes conditions called angulation, Peyronie’s disease and cavernosal fibrosis

* If you have an illness that can cause erections which won’t go away (priapism). These include sickle cell disease, multiple myeloma and leukaemia

* If you have stomach ulcers (also called gastric or peptic ulcers)

* If you have a bleeding disorder (such as haemophilia)

* If you are using any other treatments for erection difficulties

* If you experience sudden decrease or loss of vision, stop taking Levitra and contact your doctor immediately


Extracted from European Medicines Agency package leaflet information. (EMEA/H/C/475, August 2008)